Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Evista
(United States) [Available]Synonyms :
Raloxifene
Class :
Anticancer & Hormonal agents
Brand Name :
Evista
(United States) [Available]Synonyms :
Raloxifene
Class :
Anticancer & Hormonal agents
Dosage forms & Strengths Â
TabletÂ
60 mg Â
For postmenopausal females:
60
mg
Orally 
once a day
Note: ensure adequate calcium and vitamin D intake during therapy, recommended intake of vitamin D is 400-800 IU daily
5 years of duration of therapy for postmenopausal females:
60
mg
Orally 
once a day
The duration can be modified for use longer than 5 years depending on the disease progression and symptoms
Limitations of raloxifene therapy:
No specific recommendation is available for the effectiveness of raloxifene in breast cancer associated with BRCA1 and BRCA2
Not indicated for the reduction of the risk of recurrence of breast cancer
Not recommended for reduction in risk of non-invasive breast cancer
Dose Adjustments
Use with caution if creatinine clearance is <50 ml/minute
No significant data available for dose adjustment for hepatic impairment
Not determined Â
ospemifene may diminish the therapeutic effects of raloxifene or may enhance adverse toxic effects of raloxifene
It may diminish the absorption when combined with bile acid sequestrants
may enhance the concentration of serum when combined with OAT1/3 substrates
apalutamide will increase the excretion of raloxifene and decrease the therapeutic effect
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
raloxifene decreases the therapeutic effects of famciclovir by aldehyde dehydrogenase inhibition
may increase GI absorption of levothyroxine and decrease serum levels
When raloxifene is used together with ouabain, this leads to reduction in raloxifene excretion
aminohippuric acid has the potential to reduce the excretion of raloxifene
may increase the serum concentration of OAT1/3 substrates
may result in a significant increase in zavegepant exposure
may diminish the serum concentration of each other when combined
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
the rate of excretion of raloxifene may be reduced
 Actions and spectrum: Â
Raloxifene binds to the estrogen receptors. It blocks the estrogen-antagonistic effect and activates he estrogen-agonistic effect in tissues that express the estrogen receptors.Â
Frequency defined:Â Â
>10%Â Â
Leg cramps Â
Muscle spasm Â
Flu-like symptoms Â
Peripheral edema Â
1%-10%Â Â
Chest pain Â
Neuralgia Â
Insomnia Â
Skin rash Â
Weight gain Â
Sinusitis Â
Laryngitis Â
Pneumonia Â
<1%Â Â
Decreased serum cholesterol Â
Cerebrovascular accidentÂ
Black Box Warning  Â
None Â
Contraindication/Caution:Â Â
Contraindication:Â Â
Deep venous thrombosis Â
Pulmonary embolism Â
Renal vein thrombosis Â
Smoking
Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation:Â
Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â Â
Raloxifene is an estrogen receptor modulator which belongs to second-generation SERM agents. Â
Pharmacodynamics:Â
Raloxifene has anti-estrogenic activity on breast tissues and uterine endometrium and estrogenic activity on lipid and bone metabolism.Â
Pharmacokinetics:Â Â
Limited information available on ADME. Â
Administration:Â Â
It is administered orally as oral dosage forms. Â
Patient information leafletÂ
Generic Name: raloxifeneÂ
Pronounced: ra-LOX-ih-feenÂ
Why do we use raloxifene?Â
Raloxifene is used to treat osteoporosis by increasing bone density and reducing the risk of fractures. It helps prevent bone loss that typically occurs after menopause.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
